Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2720]
News [7195]
Articles [285]
Editorials [8]
Conferences [215]
elearning [41]
Major study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms
Major study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms
WCLC 2025: Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
WCLC 2025: Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
WCLC 2025: Novel immunotherapy strategy shows promising long-term survival in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors
WCLC 2025: Novel immunotherapy strategy shows promising long-term survival in advanced NSCLC patients with...
WCLC 2025: Circulating tumour DNA may guide immunotherapy use in limited-stage SCLC, new study shows
WCLC 2025: Circulating tumour DNA may guide immunotherapy use in limited-stage SCLC, new study shows
WCLC 2025: New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer
WCLC 2025: New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer
WCLC 2025: Clinical trial suggests immunotherapy before surgery is a potential new treatment for rare cancer
WCLC 2025: Clinical trial suggests immunotherapy before surgery is a potential new treatment for rare cancer
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
WCLC 2025: First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery immunotherapy combination for patients with operable mesothelioma
WCLC 2025: First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery...
WCLC 2025: Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds
WCLC 2025: Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds
WCLC 2025: Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC
WCLC 2025: Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation